United States — Food and Drug Administration & Eisai

United States — Food and Drug Administration: Approved Leqembi Iqlik on July 13, enabling the US launch.

Eisai: Partner responsible for development and commercialization; launched Leqembi Iqlik in the US, expanding its Alzheimer's franchise.

United States — Food and Drug Administration: The United States — Food and Drug Administration granted approval for Eribulin Mesylate Injection, enabling Lupin (company) and Natco Pharma to market a generic alternative in the U.S.

Eisai: Eisai's Eribulin Injection is the reference listed drug for the newly approved generic Eribulin Mesylate Injection, indicating potential competition and market share impact for Eisai.

United States — Food and Drug Administration: The United States — Food and Drug Administration has cleared the CareMiBrain system for use and has approved new monoclonal antibody treatments for Alzheimer's Disease, creating a market for the PET scans.

Eisai: Eisai, in collaboration with Biogen, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.

Eisai: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.